arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Asia Healthcare & Life Sciences Summit

Shaping the future of healthcare

Singapore |
Speakers include:

Bruce Liang

CIO, Ministry of Health, Singapore

Cristina Parsons Perez

NCD Alliance

Preetha Reddy

Apollo Hospitals Group


Thank you to everybody who joined us at the FT Asia Healthcare & Life Sciences Summit on 25 April in Singapore. We hope you enjoyed the inspiring keynotes, informative discussions and valuable networking opportunities.


Asia faces formidable healthcare challenges. An ageing population combined with longer life expectancy, as well as changing diets and lifestyles, are dramatically altering the region’s health profile. The surge in age-related healthcare requirements, and in the incidence of non-communicable diseases has put an additional burden on healthcare systems already struggling to cope. Governments have responded by increasing budgetary spending on healthcare infrastructure and services, and opening the door wider to private investment.

This has provided business opportunities for global and local healthcare and pharmaceuticals companies. But the huge healthcare market comes with challenges: poor distribution, lack of skilled personnel, pricing conundrums and constraining regulations, among others. Asia’s governments are adapting national healthcare policies to allow the private sector to share their healthcare load, but are mindful that they alone remain responsible for providing citizens with access to at least basic healthcare. 

How governments in Asia maintain this balance while addressing the push-and-pull of supply and demand, and how the private sector both improves and benefits from a transforming healthcare landscape is the theme of FT Asia Healthcare & Life Sciences Summit: Shaping the future of healthcare. Chief executive officers, chief medical officers and other senior business and government leaders will examine how initiatives taken today will change the healthcare geography for tomorrow. 

fallback Add to my Calendar 04/25/2017 08:00:0004/25/2017 17:05:00trueFT Asia Healthcare & Life Sciences SummitThank you to everybody who joined us at the FT Asia Healthcare & Life Sciences Summit on 25 April in Singapore. We hope you enjoyed the inspiring keynotes, informative discussions and valuable networking opportunities.----------------------------------------------------------------------------------------------------------------Asia faces formidable healthcare challenges. An ageing population combined with longer life expectancy, as well as changing diets and lifestyles, are dramatically altering the region’s health profile. The surge in age-related healthcare requirements, and in the incidence of non-communicable diseases has put an additional burden on healthcare systems already struggling to cope. Governments have responded by increasing budgetary spending on healthcare infrastructure and services, and opening the door wider to private investment.This has provided business opportunities for global and local healthcare and pharmaceuticals companies. But the huge healthcare market comes with challenges: poor distribution, lack of skilled personnel, pricing conundrums and constraining regulations, among others. Asia’s governments are adapting national healthcare policies to allow the private sector to share their healthcare load, but are mindful that they alone remain responsible for providing citizens with access to at least basic healthcare. How governments in Asia maintain this balance while addressing the push-and-pull of supply and demand, and how the private sector both improves and benefits from a transforming healthcare landscape is the theme of FT Asia Healthcare & Life Sciences Summit: Shaping the future of healthcare. Chief executive officers, chief medical officers and other senior business and government leaders will examine how initiatives taken today will change the healthcare geography for tomorrow. FT-Asia-Healthcare-&-Life-Sciences-Summit7f73540bcb392ac52243a773d0456839MM/DD/YYYY

Photo Gallery

Click to view

Executive Summary

Executive Summary

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

For more information about how we use your data please refer to our privacy and cookie policies.

Invites and offers from the FT

Receive exclusive personalised events invitations, carefully-curated offers, future speaking engagements and promotions from Financial Times Live

Thank you for submitting your details. Please download the event brochure.

Brochure downloads

Download Agenda

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

For more information about how we use your data please refer to our privacy and cookie policies.

Invites and offers from the FT

Receive exclusive personalised events invitations, carefully-curated offers, future speaking engagements and promotions from Financial Times Live

Thank you for submitting your details. Please download the event brochure.

Twitter feed


Follow us on Twitter:


Keynote Speakers (3)

Bruce Liang

CEO, Integrated Health Information Systems
CIO, Ministry of Health, Singapore

Bruce Liang is Chief Executive Officer (CEO) of Integrated Health Information Systems (IHiS) and Chief Information Officer (CIO) of the Ministry of Health (MOH), Singapore. Between these two roles, Mr Liang has overall responsibility for advancing healthcare information technology (IT) in Singapore. This includes IT funding, policy development, strategy, plan, implementation and operations of country-wide programmes and capabilities. As CEO of IHiS, Mr Liang is also overall responsible for the delivery of Health IT services to all public healthcare institutions.


Prior to joining MOH and IHiS, Mr Liang was with Accenture for 19 years. He held various leadership roles, including Partner for Growth and Operations of ASEAN Products Practice as well as the Health and Public Sector Practice in Asia Emerging Markets. He has extensive experience in complex and large-scale enterprise planning and Business-IT transformation programmes for governments and large businesses across Asia. Mr Liang currently holds Directorship on the Board of Assurity Trusted Solutions. He also sits on the Executive Committee of Singapore Computer Society and the Executive Council of Information Technology Management Association. Mr Liang graduated from the National University of Singapore Department of Information Systems and Computer Science in 1994.

Cristina Parsons Perez

Capacity Development Director
NCD Alliance

Cristina Parsons Perez is the Capacity Development Director for the NCD Alliance, where she is responsible for initiatives supporting national and regional civil society to drive improvements in non-communicable disease (NCD) prevention and control. She oversees the Global NCD Alliance Forum and efforts to meaningfully involve people living with NCDs in the NCD response. Dr Parsons Perez has more than 10 years of health advocacy and capacity development experience. Prior to the NCD Alliance, she consulted with Catalyst Consulting Group on advocacy capacity building and was involved in the conceptualising and roll-out of United Patients Academy – a digital training platform for health non-governmental organisations (NGOs). She worked at the American Cancer Society's Global Health Department, where she was Director of Advocacy and helped lead efforts targeting the 2011 UN High level Meeting on NCDs. She supported the establishing of the Latin American advocacy coalition for women’s cancers (ULACCAM) and oversaw multi-million multi-country capacity development initiatives to strengthen the cancer movement in the Latin American region. As a Senior Policy and Information Officer at Breakthrough Breast Cancer UK (Breast Cancer NOW), she managed grassroots advocates and developed policies to support campaigning efforts. She has a PhD in gene therapy and her mother tongues are Portuguese, Spanish and English.

Preetha Reddy

Apollo Hospitals Group

Preetha Reddy is Vice-Chairperson of Apollo Hospitals Group, an Asian healthcare provider and a proponent of integrated healthcare. She works closely with the group’s clinicians in introducing contemporary protocols to enhance clinical outcomes, leads the thrust for continuous quality improvement processes, and has spearheaded a focus on data-driven decision-making. Ms Reddy is the Managing Trustee of the Apollo Hospitals Education Trust and steers Apollo Knowledge, a consortium of healthcare educational research institutions. She works closely with the government of India to advance policy decisions on healthcare. She was a Founding Member of the Quality Council of India, an autonomous body set up by the Indian government jointly with industry. Ms Reddy also is a member of the India-US CEO Forum and India-Malaysia CEO Forum. A nominated member of the Council of Scientific and Industrial Research in India, she is on the Governing Council of NATHEALTH, a forum in India that brings together healthcare stakeholders with policy-makers.

Speakers (22)

Colin Albert

Commercial Head and Regional General Manager FMI, Roche Pharma APAC
Roche Singapore

Colin Albert is Commercial Head and Regional General Manager FMI for Roche Pharma APAC. He is responsible for leading Strategy and Business Effectiveness and driving business success in Asia. In this role, he works closely with pharma development and partnering bodies to ensure new molecules are made available to Asia-Pacific patients as early as possible. In October 2016 he established the Roche Pharma FMI Division in the Asia-Pacific region, with the aim of championing the Precision Medicine Initiative through the FMI (Foundation Medicine) range of products, which is based on the latest next-generation sequencing technology coupled to an extensive knowledge base. Mr Albert has extensive experience in the pharmaceuticals sector, with more than 10 years of international business know-how across a diverse range of cultures, which included as an Emerging Markets International Business Leader based in Switzerland and a Business Effectiveness and Strategy role based in Shanghai. Prior to his current role, Mr Albert held various sales and marketing roles in Australia for Roche as well as AstraZeneca. He holds a BA in Economics and Politics, and a Graduate Diploma in Management; he is also a Graduate of the Australian Institute of Company Directors.

Joyce Chang

Director, Asia-Pacific
Joint Commission International

Joyce Chang is Director, Asia-Pacific, with Joint Commission International (JCI). She is responsible for building and managing strategic relationships with Asia-Pacific healthcare organisations, ministries of health, government and international aid agencies, leading academic medical centres and hospitals, and other organisations committed to improving quality and patient safety. Prior to joining JCI, she focused on government and business financing, as well as hospital solutions within the Greater China market as a strategic account manager for Philips Medical Systems. Ms Chang also served as a consultant at The ChinaCare Group, where she concentrated on organisational restructuring, worked closely with decision-makers in the Chinese medical industry. As a management analyst at New Century International Children’s Hospital in Beijing, she managed continuous quality improvement projects and was part of the executive committee to improve profitability. Awarded Peking University’s Young Health Economist Scholarship, Ms Chang completed a research fellowship at the university’s China Center for Pharmacoeconomics & Outcomes Research. She is co-author of the World Bank Group-commissioned China Urban Service and Governance Study Health Report, an in-depth profile of China’s healthcare infrastructure. Ms Chang earned her master’s degree in health services administration and globalisation of health and her bachelor’s degree in cellular molecular biology from the University of Michigan in the US.

Erwan Barre

Partner (Foreign Lawyer)
RHTLaw Taylor Wessing LLP

Erwan Barre is Partner (Foreign Lawyer) with RHTLaw Taylor Wessing LLP. He joined the firm in 2015 after practising for 16 years with Sullivan & Cromwell and Paul Hastings, two leading US law firms, in Paris and New York. Focused on corporate transactions, Mr Barre has extensive experience representing clients across many industries, with an emphasis on Technology and Life Sciences. He also has management experience, being a co-founder of Vaximax, a biotech company. Mr Barre has been involved in many M&A, joint venture, capital markets and financing projects in Asia, Europe and the US. Most of these deals were cross-border. His transactional expertise is based on leading over 60 deals, representing a total of more than US$20 billion. Fully 60% of his transactions involved telecommunications, media and technology, and life sciences companies. Mr Barre holds an MBA from the Neoma (ESC Reims) Business School in France (1990), a pre-doctoral degree (DEA) in business law from the Pantheon-Sorbonne (Paris I) University (1993), and an LL.M. degree from Columbia University in the US (1996). Mr Barre has worked in Singapore, Paris, New York and London. He is admitted in France (1996) and New York (1998). He is registered as a foreign lawyer in Singapore.

Peter Fang

Head of Asia-Pacific

Peter Fang is Head of Asia-Pacific at Shire, a leading global biotechnology company that focuses on rare diseases and specialty medicines. Mr Fang has responsibility for Shire’s operations in the region, with its headquarters based in Singapore. Prior to Shire, Mr Fang spent more than 14 years at Baxter / Baxalta’s Hematology and Immunology divisions in a variety of global, regional and country commercial roles in the United States, Switzerland and the United Kingdom. He was most recently responsible for the commercial operations of over 40 small- and mid-sized markets across Europe, Middle East and Africa. Mr Fang has earlier experience working in venture capital and in technology start-ups in Silicon Valley, and started his career in management consulting. He has a degree from the Wharton School of the University of Pennsylvania. Originally from Chicago, Illinois, Mr Fang spends his time in London and Singapore.

Rebecca George

Global Lead for Public Sector Health Care and Social Services

Rebecca George OBE leads Deloitte’s Public Sector practice in the UK. She is Global Lead for Public Sector Health Care and Social Services. She is responsible for the work Deloitte does across the Public Sector, including Health, Education, Transport, Defence, National Security, Justice and Home Affairs, and Central and Local Government. Ms George leads Deloitte’s global health strategy implementation, capability building and business development. Her recent work has focussed on the health sector, specialising in clinical transformation enabled by technology. Working with central organisations and providers, she has supported the development of clinically led strategies, business cases, funding mechanisms, procurements and implementations of health technology systems. This work was often in the context of health economy restructuring, service reconfiguration, or merging organisations.

Ms George has worked exclusively with the Public Sector for 15 years. She is a senior business manager with practical experience of managing businesses and improving operational efficiency. She joined Deloitte as a Partner in 2006 after spending nearly 20 years at IBM in a variety of roles, including sales, business process re-engineering and HR, in the UK, EMEA and globally. Ms George was honoured with an OBE in 2006 for her work for the government on sustainable communities.

How Ti Hwei

Country President, AstraZeneca Singapore;
President, Singapore Association of Pharmaceutical Industries

How Ti Hwei is Singapore’s Country President for AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas: Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. Mr How is also President of the Singapore Association of Pharmaceutical Industries, comprising 34 global pharmaceuticals companies, with the goal of making innovative medicines accessible to patients in Singapore through sustainable and valued partnership with healthcare professionals and providers, government, payers and patient group stakeholders. Mr How has more than 20 years’ experience across both the pharmaceuticals and fast-moving consumer goods industries. He has worked and lived in Singapore, Malaysia, Vietnam, Thailand and the Philippines. A Singapore national, Mr How was educated and trained as a pharmacist and holds an MBA from the National University of Singapore.

Srividya Jagannathan

Global Lead for Lifesciences
International Finance Corporation

Srividya Jagannathan is the Global Lead for Lifesciences at the International Finance Corporation (IFC), a member of the World Bank Group. IFC’s investments in this sector include Glenmark Pharmaceuticals, Jubilant Pharmaceuticals, Fosun Pharmaceutical, Weigao, B Braun and Recordati. Ms Jagannathan has 20 years of experience across private equity, debt structuring and corporate finance in various emerging markets, and across the pharmaceuticals, chemicals and construction-materials sectors. Prior to joining IFC, she was a Senior Vice-President at Lehman Brothers, a global investment bank, covering private equity and public market investments for India. She also has worked with J.P. Morgan, a global investment bank, and Standard & Poor’s, an international rating agency. Ms Jagannathan holds an MBA from the Xavier’s Institute of Management, India.

Yi Mien Koh

Group Medical Director

Yi Mien Koh is Group Medical Director of AIA, a leading life insurer that operates in 18 markets in the Asia-Pacific region. Dr Koh’s career in healthcare spans every level of the health system, in the UK, Australia and Asia. She has served as CEO of a health authority and a teaching hospital in London. She has also been a Chief Medical Officer in Australia, Medical Director and Director of Performance in London, and clinical advisor to health regulators in the UK. Dr Koh was an honorary professor at the London School of Hygiene and Tropical Medicine and is an adjunct professor at James Cook University, Australia. A public health physician by background, Dr Koh studied medicine at Melbourne University and received her specialist training in the UK and Australia. She has an MSc in public health medicine from the London School of Hygiene and Tropical Medicine, an MBA from Cass Business School and a DBA from Cranfield University, UK. Dr Koh is a Fellow of the UK Faculty of Public Health, the Royal Australasian College of Physicians and the Royal Australasian College of Medical Administrators. She is also a Fellow of the UK Chartered Institute of Personnel and Development.

Maarten Kelder

Senior Vice-President, Strategy and Solutions
Zuellig Pharma

Maarten Kelder is Senior Vice-President, Strategy and Solutions, Zuellig Pharma. He works alongside Zuellig Pharma’s CEO and Executive Management team to set and drive the company’s overall strategic direction. He leads Zuellig Pharma’s solutions businesses, spearheading the growth of its digital, data analytics, channel and patient care operations. Mr Kelder joined Zuellig Pharma in 2015, bringing with him more than 20 years’ experience in strategy development for multinational corporations and local Asian companies. Prior to Zuellig Pharma, he was the lead partner of Monitor Deloitte in Asia where he focused on corporate and business unit strategy; growth and innovation strategy; portfolio strategy and restructuring; partnering and M&A strategy; and organisational capability development. Mr Kelder graduated with BSc and MSc degrees from the University of Technology in Delft, Holland. He also holds an MBA from Tuck School of Business at Dartmouth College in the US.

Ramesh Kumar

Head of the APAC Sub-region
Ascensia Diabetes Care

Ramesh Kumar is Head of the APAC Sub-region at Ascensia Diabetes Care. He is responsible for business in the sub-region, which accounts for 17 countries. For over 15 years, Mr Kumar has been with Panasonic Healthcare, which manufactures a leading brand in the Self Blood-Glucose Monitoring field. At Panasonic Healthcare, he has completed the 1st business process cycle and an “Investigator Initiated Study” with 84 patients at a leading hospital in Indonesia. Following the sale of the Bayer Diabetes Care business to create Ascensia Diabetes Care, a company solely owned by Panasonic Healthcare Holdings in Japan, he was assigned to his current position, based in Singapore. Mr Kumar started his career as an engineer in 1990 and ventured into diversified fields over the next 26 years, including research & development and product development, entering the healthcare sector in 2010. Since then, he has gained experience in healthcare as a Business Development General Manager, Senior Manager, Business Planning, and Clinical Development General Manager. Mr Kumar holds a Bachelor of Engineering degree in Instrumentation & Control Engineering, a Master of Science degree in Mechanics and Processing of Materials, and a Master of Business Administration degree in General Management.

Allen Lai

Regional Managing Director
ACT Genomics Singapore

Allen Lai is Regional Managing Director of ACT Genomics Singapore, strategising corporate development, planning and execution of cancer genomics clinical & research projects in South-east Asia. He holds high-profile roles as Advisor Board of ISPOR Asia Consortium, President of ISPOR Singapore and concurrently Senior Consultant, Ministry of Health and Social Welfare, Taiwan. Dr Lai previously was principal consultant at IMS Health Asia, director of the Institute of Health Economics & Management and academic director of MSc Management of Health Industries in ESSEC Business School. He received his PhD and MPA from Lee Kuan Yew School of Public Policy, National University of Singapore, MSc (Preventive Medicine) from National Taiwan University and MD from Chung Shan Medical Dental University, Taiwan.

Priya Matzen

Associate Director, Market Access and Public Affairs, South-east Asia
Novo Nordisk

Priya Matzen is Associate Director, Market Access and Public Affairs, South-east Asia, Novo Nordisk. She is responsible for supporting South-east Asian countries in developing robust market access and public affairs strategies to strengthen diabetes leadership and expand access. She has 14 years of strategic and operational experience in market access and public affairs from global, regional and country roles. Ms Matzen is passionate about strengthening health systems to tackle non-communicable diseases and improving maternal and child health; she is currently spearheading a research project on women and diabetes, a public-private partnership with the Ministry of Health, Malaysia, and global academic partners. She has been leading and developing many of Novo Nordisk’s strategic programmes contributing to the company’s commercial success and its reputation and positioning as a value-added partner in the fight against diabetes in collaboration with governments, non-governmental organisations and multilateral agencies. Ms Matzen started her career as a consultant at Ernst & Young and received her business training from INSEAD Business School. She holds an MSc in Environmental Management and Policy and a master’s degree in Pharmacology and Environmental Toxicology. She has published on the prevention of diabetes, and is a visiting fellow at the University of Southampton, UK.

Sumit Mody

General Partner and Head of Investments
Health Passion Fund

Sumit Mody is General Partner and Head of Investments at Health Passion Fund, which seeks to invest in healthcare innovations and start-ups, primarily in South Asia. A career investor with a focus on the portfolio approach in angel investing, Mr Mody’s last assignment was to start a Healthcare Innovations Fund for the co-founder- chairman of iGate, an information technology services company, and integrate its impact funding. Previously, he was Head of Private Equity at Essel Finance, an umbrella brand for the financial businesses of the Essel Group; Vice-president at Pramerica BHI (the Indian partner of US$35-billion Pramerica Global Investors, a subsidiary of Prudential); Head of Asian Investments in London for Rhodius Partners, an advisory set-up with US$6 billion of transactions track record; and a banker in Dubai and India. Mr Mody has been involved in setting up from scratch sizeable financial services and retail business ventures in Asia, the UK and Gulf Co-operation Council member-states. He holds a master’s degree in finance from the London Business School.

Jean Nehme

CEO and Co-founder
Digital Surgery

Dr Jean Nehme MBBS BSc MRCS MSc (Hons) is the co-founder and CEO of Digital Surgery. Jean co-founded Digital Surgery whilst training in Plastic Surgery in London with Dr Andre Chow. Dr Nehme has multiple awards for his research in innovation and application of surgical technology and simulation. He was named by Debrett's as one of the most influential 500 people in the UK. Digital Surgery is a health tech company shaping the future of surgery through the convergence of surgical expertise and technology. At this time when the healthcare industry is facing multiple challenges globally, Dr Nehme strongly believes the solutions lie in leveraging on technological advancements to bring safe, accessible surgical care for all.

Laxmikant Palo

Regional Director, South-east Asia
Project HOPE

Laxmikant Palo is Regional Director, South-east Asia, with Project HOPE, an international non-profit organisation working in 35 countries to provide lasting solutions to health problems, with the mission of helping people to help themselves. Dr Palo currently manages public health programmes in six countries in South-east Asia, with a major focus on diabetes and hypertension prevention and care. He has more than 24 years’ experience in public health, in programme planning and management, evidence-based policy advocacy, partnership management and public health technical assistance to government and project implementing partners. Dr Palo has worked with a diverse range of national and international organisations such as Save the Children, USAID, IntraHealth International, PATH, FHI360 and DFID, focusing on improving healthcare for the under-served communities across the world. He holds a PhD in public health and nutrition.

Peng Chung Mien

Group CEO
The Farrer Park Company

Peng Chung Mien is Group CEO of The Farrer Park Company, which he joined in April 2014. A medical doctor by training, he has more than 30 years of experience in both healthcare management and business operations. Prior to joining The Farrer Park Company, Dr Peng was CEO of ST Medical Services and Executive Vice-President of Healthcare Logistics of ST Logistics. He also spent 20 years serving in the Republic of Singapore Air Force, and was the pioneer Chief Air Force Medical Officer. Dr Peng is a graduate of the INSEAD Advanced Management Programme and holds an MBA from the National University of Singapore as well as a Master’s in Public Health from Harvard University. He is an accredited specialist in Aviation Medicine, a Fellow of the Aerospace Medical Association, and an Academician at the International Academy of Aviation & Space Medicine.

Roy Quek

Executive Chairman
Thomson Medical Group

Roy Quek is Executive Chairman of Thomson Medical Group, a position he has held since November 2015. Prior to joining the Thomson Medical Group, Mr Quek was a member of the Administrative Service of the Singapore Government. In his 20-year stint in public service, he served in the Ministries of Defence, Education, Community Development, Youth and Sports, Health and Home Affairs. He was also the Founding Director of the National Population Secretariat in the Prime Minister’s Office. Mr Quek served as Deputy Secretary in the Ministry of Health and the Ministry of Home Affairs before he left to join the private sector. For his work in the Singapore public sector, he was conferred the Public Administration Medal (Silver) in 2008. Aside from his work in leading the Thomson Medical Group, Mr Quek chairs the Board of Governors of St Joseph’s Institution International, an independent not-for-profit school in Singapore that ranks among the top-performing private international schools in Asia. He also serves on the Board of Directors of MediaCorp, Singapore’s national broadcaster. An economist by training, Mr Quek received his undergraduate and postgraduate education at the London School of Economics and Peking University, respectively.

Sajid Rahman

Telenor Health

Sajid Rahman is CEO of Telenor Health, which is built to deliver quality, data-driven healthcare in emerging markets. Wholly owned by the Telenor Group, Telenor Health launched its first proposition, Tonic, in Bangladesh, and currently serves millions of people.

Mr Rahman is also an international banker with experience in the emerging markets of South Asia, Southeast Asia, the Middle East and Africa; he previously worked for Standard Chartered Bank. He has board-level experience in banks, managing a wide range of businesses and taking them through mergers and acquisitions.

Mr Rahman has brought to Bangladesh the first Silicon Valley-based accelerator, Founder Institute, of which he is a director. He is a mentor at Endeavor Indonesia, a US-based organisation accelerating the growth of mid-size companies to billion-dollar businesses. An active angel investor, Mr Rahman sits on the boards of a number of technology and renewable energy companies in Asia and Europe.

Ramesh Rajentheran

Group Chief Financial & Chief Operating Officer
Fullerton Health

Ramesh Rajentheran is Group Chief Financial & Chief Operating Officer at Fullerton Health. He sits on the boards of various group subsidiaries as well as of Engineering Good, a humanitarian engineering non-profit in Singapore. Prior to joining Fullerton Health, a leading managed healthcare provider in Asia, Dr Rajentheran was in investment banking from 2004 to 2015, as a Managing Director with Barclays in Singapore and Hong Kong, Head of Markets & Advisor to the Executive Chairman at the Hong Leong Group in Kuala Lumpur, an Executive Director at Morgan Stanley in London, and an Associate Director at UBS in London. From 1999 to 2002, he was a physician with the National Health Service in the UK, where he was published in leading scientific journals. Dr Rajentheran holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from the University of Newcastle, where he was a Commonwealth/Chevening scholar, and a Master of Business Administration degree with a concentration in finance from the London Business School.

Patrick Tan Boon Ooi

Deputy Executive Director, Biomedical Research Council, Agency for Science, Technology and Research, Singapore
Professor, Duke-NUS Medical School Singapore

Patrick Tan is Deputy Executive Director of the Biomedical Research Council, Agency for Science, Technology and Research (A*STAR) in Singapore, and Professor at the Duke-NUS Medical School. He also directs PRISM, the SingHealth DukeNUS Institute of Precision Medicine. He previously was Programme Director of POLARIS, which established the first CAP-certified facilities for next-generation sequencing and the first clinically implemented NGS panel in South-east Asia. Dr Tan is an elected member of the American Society for Clinical Investigation and the Bioethics Advisory Committee, a national body that provides advice to the Singapore government on ethical issues related to biomedical research. He is also a board member of the International Gastric Cancer Association and a member of the AACR International Affairs Committee. He co-leads the biliary tract cancer project of the International Cancer Genome Consortium, and is co-chair of the Singapore National Precision Medicine Program Steering Committee. Dr Tan received his BA (summa cum laude) from Harvard University and MD PhD degree from Stanford University, where he received the Charles Yanofsky prize for Most Outstanding Graduate Thesis in Physics, Biology or Chemistry. His other awards include: the President’s Scholarship, Loke Cheng Kim scholarship, Young Scientist Award (A*STAR), Singapore Youth Award (twice) and SingHealth Investigator Excellence Award.

Isabel Torres

Global Head of Access to Medicines
Takeda Pharmaceuticals

Isabel Torres is Global Head of Access to Medicines with Takeda Pharmaceuticals. Since joining Takeda in May 2015, she has been instrumental to the inception, development and launch of Takeda’s new Access to Medicines strategy. In that time, she has worked closely with healthcare professionals, experts, governments, and private and public partners to devise and implement a strategy designed to have the biggest possible impact on patients, focusing on countries with less-developed healthcare systems, where Takeda’s core therapeutic areas can make the biggest difference. Ms Torres has nearly 20 years’ experience in the pharmaceuticals industry. After six years at Merck Pharmaceuticals, where she began her career, Ms Torres joined Sanofi to oversee the development and implementation of its Access to Medicines programme. As part of this, she worked closely with the World Health Organization, along with governments across Africa, South-east Asia and Brazil, to develop sustainable solutions to pandemics for patients most in need. During her 11 years at Sanofi, Ms Torres was also central to the development of the company’s Worldwide Compliance Programme, the CV/IM portfolio strategy and a new Medical Affairs Programme across Asia.

Zee Yoong Kang

Health Promotion Board, Singapore

Zee Yoong Kang is Chief Executive Officer of Singapore’s Health Promotion Board (HPB). Established in 2001, HPB’s mission is to help Singaporeans to increase the quality and years of healthy life and to prevent illness, disability and premature death. Mr Zee has served in various capacities in the Singapore government (Prime Minister's Office, Ministry of Foreign Affairs and Ministry of National Development). He has also worked in the private sector. He was a management consultant with Bain & Company, working on projects in the Heavy Engineering, Information Technology and Fast-Moving Consumer Goods sectors. After Bain, Mr Zee joined Singapore’s National Trades Union Congress (NTUC), where he founded NTUC LearningHub and the Employment and Employability Institute, also known as e2i.


Chair and Moderators (3)

Andrew Jack

Head of Curated Content
Financial Times

Andrew Jack has worked as a journalist for the Financial Times since 1990. He currently runs the curated content team, which picks the best news and analysis from the FT and the rest of the web. He was previously Deputy Editor of the Analysis section, Pharmaceuticals Correspondent, Moscow Bureau Chief, Paris Correspondent, Financial Correspondent, general reporter and corporate reporter. He is author of the books Inside Putin’s Russia and The French Exception, as well as numerous specialist reports, and has appeared on the BBC and other media outlets.

Jeevan Vasagar

Singapore Correspondent
Financial Times

Jeevan Vasagar is Singapore correspondent for the Financial Times, focusing on the financial sector. Prior to this appointment he was the FT’s Berlin correspondent, where he covered the relationship between politics and business in Germany. Before that, he spent 12 years at the Guardian, including spells covering east Africa and writing about education policy. His freelance writing has appeared in the New Statesman, the Economist and the LA Times.

Rohan Hammett

Lead Clinical Partner, Deloitte Australia
Global Lead, Financial and Operational Improvement in Healthcare

Rohan Hammett is Lead Clinical Partner, Deloitte Australia, and Global Lead, Financial and Operational Improvement in Healthcare. He has led major clinical redesign and organisational transformation processes, while helping Deloitte’s implementation team for the South Australian health system’s Transforming Health programme; developed organisational strategies and operational plans for major public and private hospital groups; and worked with life sciences companies to optimise market penetration. Dr Hammett is a consultant physician in gastroenterology, with over 25 years of experience as a clinician, health system manager and government regulator. He has worked in the Australian, US and UK health systems, and has led global cooperation initiatives across Asia, Europe and North America. He previously headed the Therapeutic Goods Administration (TGA), Australia’s national health regulator, and served on global regulatory harmonisation groups such as the Global Harmonisation Taskforce for Medical Devices. While at the TGA, Dr Hammett led a programme of regulatory reform to streamline market authorisation processes, enhance international regulatory cooperation and improve post-market safety monitoring for medicines and medical devices. He also was Deputy Director General for Australia’s largest health system, managing a multibillion operating budget and establishing new approaches to partnering with the private and not-for- profit sectors.

Agenda - 25th Apr

  • 8:00am
    Registration and refreshments
  • 9:00am
    FT chair’s opening remarks

    Andrew Jack, Head of Curated Content, Financial Times

  • 9:10am
    Keynote address: Making healthcare sustainable in Asia

    Asia’s healthcare systems are under increasing pressure. The region’s population is ageing, the incidence of non-communicable diseases (NCDs) is reaching epidemic proportions, and the healthcare infrastructure is overwhelmed. In addition, Asia’s patients are becoming more demanding about the quality of healthcare they receive. Staggering under the financial burden of providing healthcare for their citizens, many governments in the region are reforming their healthcare offerings. Greater collaboration with, and support for, the private sector; initiatives on health education; and training for healthcare personnel are some measures being considered to make healthcare sustainable in Asia. How are countries faring?

    Preetha Reddy, Vice-Chairperson, Apollo Hospitals Group

    Moderator: Andrew Jack, Head of Curated Content, Financial Times

    [Download Presentation - PDF File]

  • 9:30am
    Keynote: Intelligent technology = smarter healthcare

    Bruce Liang, CEO, Integrated Health Information Systems; CIO, Ministry of Health, Singapore

    Moderator: Jeevan Vasagar, Singapore Correspondent, Financial Times

  • 9:40am
    Panel discussion: Intelligent technology = smarter healthcare

    Technology innovation is revolutionising the healthcare industry. The biggest gamechanger is Big Data, the billions of gigabytes collated on medicines, care providers, patients, clinical outcomes and much more. This wealth of data has the potential to transform healthcare systems by re-drawing the boundaries of collaboration among different stakeholders, including investors, government and industry, and by changing the interaction between patients and healthcare suppliers. Innovations in me dical devices and wearables are already disrupting the way healthcare is delivered. Is this the way forward for Asia?

    • Given that access to basic healthcare is not a reality for the bulk of the region’s population, should governments focus policy and finance on the groundwork for good healthcare i.e. sanitation, vaccination, rural medicinal facilities instead of on high-end healthcare technology?
    • Is health tech a predominantly private-sector exercise?
    • Can healthcare start-ups compete with big companies in health tech?
    • Has the health tech industry ramped up its data security measures?

    Allen Lai, Regional Managing Director, ACT Genomics

    Bruce Liang, CEO, Integrated Health Information Systems; CIO, Ministry of Health, Singapore

    Sajid Rahman, CEO, Telenor Health

    Jean Nehme, CEO and Co-founder, Touch Surgery

    Moderator: Jeevan Vasagar, Singapore Correspondent, Financial Times

  • 10:20am
    Q&A: Legal implications of health tech—reading the fine print

    While technological innovation is shaking up the practice of medicine, it is also raising concerns among stakeholders about the legal ramifications of financing health tech products and services, intellectual property rights to technology and data privacy, among other concerns. What are the legal stumbling blocks for health tech companies, practitioners and patients, and how can they best protect themselves?

    Erwan Barre, Partner (Foreign Lawyer), RHTLaw Taylor Wessing LLP

    Interviewer: Jeevan Vasagar, Singapore Correspondent, Financial Times

  • 10:40am
    Networking break
  • 11:00am
    Presentation: Patient-centred healthcare: how workable is it in Asia?

    Although Asia’s healthcare systems in recent years have improved greatly, they largely remain overwhelmed by the demand, not only to provide adequate services but also to make them affordable. One way to ease the burden is to involve patients in their own healthcare—for example, engaging them, along with other stakeholders, in policy decisions on healthcare. Or collating information that reflects actual needs rather than simply crunching numbers, or encouraging patients towards a healthier lifestyle. The efficacy of this approach may be limited to developed environments where patients have easier access to data, but the rapid urbanisation of Asia, and the vision of building healthier cities, could mean the region’s patients playing a larger role in their own healthcare.

    Zee Yoong Kang, CEO, Health Promotion Board, Singapore

    Moderator: Jeevan Vasagar, Singapore Correspondent, Financial Times

    [Download Presentation - PDF File]

  • 11:20am
    Panel discussion: Collaboration in pharma-healthcare—stronger together

    Given the high costs of research & development (R&D) for healthcare products and services, the obligation to meet patient needs swiftly and efficiently, and the necessity to remain viable, healthcare and pharmaceutical companies are looking at partnerships as a way to reap mutual benefits. To what extent do government policies influence the collaborative process? How practical are the industry’s R&D partnerships with academia, the government or multilateral agencies?

    Patrick Tan Boon Ooi, Deputy Executive Director, Biomedical Research Council, Agency for Science, Technology and Research, Singapore; Professor, Duke-NUS Medical School Singapore

    Srividya Jagannathan, Global Lead for Lifesciences, International Finance Corporation

    How Ti Hwei, Country President, AstraZeneca Singapore; President, Singapore Association of Pharmaceutical Industries

    Isabel Torres, Global Head of Access to Medicines, Takeda Pharmaceuticals

    Moderator: Rohan Hammett, Lead Clinical Partner, Deloitte Australia, Global Lead, Financial and Operational Improvement in Healthcare

  • 12:10pm
    Panel discussion: The business of healthcare

    Spurred by Asia’s economic growth and government reforms in the sector, the region’s healthcare and pharmaceuticals market has become an attractive destination for global companies, which are investing in expansion of production and research facilities or launching new operations. External financiers, too, are looking at the industry’s potential to make profits, especially in start-ups, small hospitals and digital health initiatives.

    • Where are the greatest opportunities in Asia, and the most prolific investment activity for established companies and newcomers?
    • What are the biggest challenges?
    • To what extent has China’s economic slowdown shifted the dynamics of the region’s healthcare and pharmaceuticals market?
    • Is heightened competition from domestic companies aiding or hindering healthcare and pharmaceuticals investment and operations?

    Sumit Mody, General Partner and Head of Investments, Health Passion Fund

    Colin Albert, Commercial Head and Regional General Manager FMI, Roche Pharma APAC, Roche Singapore

    Peter Fang, Head of Asia-Pacific, Shire

    Moderator: Andrew Jack, Head of Curated Content, Financial Times

  • 12:50pm
  • 2:00pm
    Panel discussion: Medical tourism—Asia’s other attraction

    Patients from overseas are spending billions of dollars in Asia’s hospitals for treatment and surgery, especially for cancer and cardiovascular procedures. At some of the region’s best medical institutions, the medical tourists get top-notch services at a fraction of the cost back home. For their part, the hospitals get a steady stream of revenue, part of which can be ploughed back into improving facilities and services. India, Singapore, Thailand and Malaysia are among the best-known medical tourism destinations, with strong government support. But there are practical and policy issues to consider:

    • How can potential patients ensure the quality of their proposed treatment?
    • What about after-care?
    • In cases of malpractice or negligence, what recourse do patients have?
    • How do governments politically balance providing state-of-the-art facilities to foreigners with their own citizens’ difficulties in accessing basic healthcare?

    Joyce Chang, Director, Asia-Pacific, Joint Commission International

    Peng Chung Mien, Group CEO, The Farrer Park Company

    Roy Quek, Executive Chairman, Thomson Medical Group

    Moderator: Andrew Jack, Head of Curated Content, Financial Times

  • 2:40pm
    Panel discussion: Health insurance: Who’s paying the bills?

    Until a few decades ago, the responsibility to provide universal affordable healthcare fell on the government. The private sector meanwhile catered to the rising middle class and the affluent, providing better quality services at a higher price. An over-burdened healthcare infrastructure, however, has compelled many an Asian government to legislate a national health insurance system as a safety net for its citizens. Implementation has left much to be desired. Meanwhile, buying private health insurance has continued to be expensive.

    • How viable is a national health insurance system?
    • Can public-private partnerships be the answer to finance public healthcare?
    • Does private healthcare insurance lead to higher healthcare spending?
    • To what extent does private healthcare insurance result in better quality healthcare and health personnel?
    • What regulatory challenges face private health insurers in Asia?

    Yi Mien Koh, Group Medical Director, AIA

    Rebecca George, Global Lead for Public Sector Health Care and Social Services, Deloitte

    Ramesh Rajentheran, Group Chief Financial & Chief Operating Officer, Fullerton Health

    Moderator: Andrew Jack, Head of Curated Content, Financial Times 

  • 3:30pm
    Networking break
  • 3:50pm
    Keynote address: Rise of non-communicable diseases in Asia

    As economic growth slowly raises standards of living in Asia, it is also increasing the incidence of non-communicable diseases. Greater affluence has led to unhealthy diets that are high in salt and fat, and a sedentary lifestyle, both of which are contributing to a surge in cases of cancer, heart disease, respiratory problems and diabetes, among other NCDs. So pervasive and swift has been their spread that many Asian countries are scrambling to construct forceful response strategies. Not only do healthcare systems have to provide care and cure for patients, but they also must control and prevent NCDs. Have the region’s governments begun to formulate effective national plans and policies to counter the NCD problem?

    Cristina Parsons Perez, Capacity Development Director, NCD Alliance

    Moderator: Jeevan Vasagar, Singapore Correspondent, Financial Times

    [Download Presentation - PDF File]

  • 4:10pm
    Panel discussion: A closer look at diabetes in Asia

    Often called the Silent Killer, diabetes has spread rapidly worldwide, and incidence is continuing to rise. According to the International Diabetes Federation, there were 415m people in the world with diabetes in 2015; in 2040 there will be 642m. Asia accounts for more than half of the cases—in 2015, Southeast Asia and Western Pacific recorded 78.3m and 153.2m diabetes sufferers, respectively; in 2040, these figures will have climbed to 140.2m and 214.8m, respectively. Clearly, the situation requires quick action and sound policy from governments, but multilateral agencies and the private sector also can make vital contributions. So can social media.

    • How are multilateral agencies and non-profit organisations working with governments to address the problem?
    • What proportion of public financial resources should be channelled into creating awareness for prevention and control of diabetes?
    • Can online communities in Asia help to spread information and awareness of diabetes?
    • What role should the private sector play in relieving the burden?
    • Is the burgeoning treatment market leading to competitive research and development in diabetes?

    Ramesh Kumar, Head of the APAC Sub-region, Ascensia Diabetes Care

    Laxmikant Palo, Regional Director, South-east Asia, Project HOPE

    Priya Matzen, Associate Director, Market Access and Public Affairs, South-east Asia, Novo Nordisk

    Maarten Kelder, Senior Vice-President, Strategy and Solutions, Zuellig Pharma

    Moderator: Jeevan Vasagar, Singapore Correspondent, Financial Times

  • 5:00pm
    FT chair’s closing remarks

    Andrew Jack, Head of Curated Content, Financial Times

  • 5:05pm
    Cocktail reception

Why Attend?

  • Hear viewpoints on how to make healthcare sustainable
  • Listen to news and analysis on technological innovation in healthcare, as well as its legal challenges
  • Explore how to pay for healthcare--a critical element in countries with high costs of private services
  • Get input from patients on what they want in healthcare
  • Learn more about the risks of non-communicable diseases, especially diabetes

Who Attends?

FT Live has a reputation for delivering senior level audiences to world class thought-leadership events across the globe for nearly 40 years.

These are just some of the companies that attended FT Asia Healthcare & Life-Sciences Summit 2016:

  • Abbvie
  • Actavis
  • Actelion Pharmaceuticals
  • Agency for Science, Technology and Research (A*STAR)
  • Alcon Laboratories, Inc.
  • Asian Trade Centre
  • ASLAN Pharmaceuticals
  • Astellas Pharma Singapore Pte. Ltd.
  • Baxter
  • Bayer
  • British High Commission
  • Carestream Health Singapore Pte Ltd
  • Chipscreen Biosciences
  • Deallus Consulting Japan KK
  • Deloitte
  • DFE Pharma
  • Duke-NUS Medical School
  • Esco Micro Pte Ltd
  • EY
  • Fresenius Medical Care Asia Pacific Ltd.
  • GlaxoSmithKline
  • Hillgenberg Consulting
  • Human Longevity Singapore
  • Hutchison China MediTech
  • IMS Health
  • Johnson & Johnson
  • KPMG
  • McCann Healthcare Singapore
  • Merck Sharp & Dohme
  • MT Pharma Singapore
  • Mundipharma
  • Nestle Skin Health
  • Novartis
  • Omron Healthcare Singapore
  • Pfizer
  • Polaris Life Sciences
  • Roche
  • Sanofi
  • Santen Pharmaceutical
  • Veeva
  • Zuellig Pharma

Why Sponsor?

These are just a few of the many reasons to consider a commercial partnership with the Financial Times for the FT Asia Healthcare & Life Sciences Summit 2017:

  • Showcase your company’s solutions to a targeted and relevant audience
  • Gain direct access to senior decision makers across the healthcare supply chain
  • Benefit from brand alignment with the FT and its unrivalled credibility
  • Learn more about the specific interests and activities of your client base


The Westin Singapore
12 Marina View, Asia Square Tower 2


Tel: +65.6922.6888


Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT marks 130 years in 2018 with a record paying readership of more than 940,000, three-quarters of which are digital subscriptions. It is part of Nikkei Inc, which provides a broad range of information, news and services for the global business community.

With the support of (1)

About Life Sciences and Health Care at Deloitte*

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information, visit or email

*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Supporting Partners (2)

The Association of Medical Device Industry (Singapore) [hereinafter referred as AMDI] was incorporated in January 2011. AMDI serves as a key representative body for the medical device industry in Singapore. It aims to advocate good practices and promote high industry standards among the trade.

Our Mission:

• To be a leading Association that will provide a credible platform for the Medical Device Industry to offer Quality, Professional and Networking Resources

• To offer a worthy platform to allow members the opportunity to advance and grow in the industry

• To be a credible representative of the Medical Device Industry in Singapore, continuously promoting quality and professionalism for the good of the industry

Our Objectives:

a) To represent the Medical Equipment and Medical Device Industry in Singapore in the engagement and dialogue with regulators and effective dissemination of information to industry members.

b) To have our interest and concerns be heard by the government agencies.

c) To assist Small & Medium Enterprises to position for advancement and create an environment for greater opportunities and growth.

d) To organize trade missions for members.

e) To co-operate with various trade commissions.

f) To promote and enhance industry standards.

g) To act as a platform for members to interact and network


Email :

Founded in 1958, Project HOPE is dedicated to providing lasting solutions to health problems by helping people to help themselves. Identifiable to many by the SS HOPE, the world’s first peacetime hospital ship, Project HOPE now provides medical training and health education and humanitarian assistance programs in more than 30 countries with a major presence in Asia.

Project HOPE works at the epicenter of today’s greatest health challenges by enabling health care workers to have the greatest positive impact on the health of people they serve. Our expertise includes global NCDs, infectious diseases, maternal, neonatal and child health, health policy and responding to disasters and health crises.

Project HOPE remains as committed as ever to addressing the world’s new health threats by playing a leadership role in forging new alliances among those on the frontlines of health and together seeking new solutions. Learn More

Supporting Media Partners (10)

Since 2004, Asia Research News has been helping Asia’s universities and research institutions promote new research findings and academic expertise to a wider international audience, including the media. Our services include specialist writing and targeted media distribution. Our news portal,, helps connect Asian researchers with the media and the public. We also publish the annual magazine, Asia Research News magazine, which highlights innovative and significant breakthroughs from Asia.

Asian Scientist Magazine is a print and online magazine that covers breaking R&D news and feature stories from the Asian scientific and medical community. The magazine is dedicated to providing healthcare professionals, researchers, government agencies, educators and students with timely, close-to-the-scene information from Asia.

Bentham Science Publishers is offering a substantial discount on publications:

- All printed books/eBooks ordered or purchased will be discounted for 30%.

- All PPV journal articles purchased will be discounted by 20%.

Readers can choose any eBook from our catalog of over 600 publications in a variety of scientific fields. Catalog is listed here.

Our PPV articles are categorized by disease and can be accessed here.

To avail these discounts, simply use the code “BSPPRTC016” on our e-store while purchasing your e-book or article. There is no limit on the number of purchases on discounted books or articles.

For more information about this offer or to place your order, contact our office.

For eBooks:

With a focus on Greater China's growing life sciences sector, BiotechEast is a Taiwan-based consultancy offering international biotech companies, institutes and investors the resources and services they need to find opportunities in the region. From drug discovery to pharma, from med-tech to med-device, from herbal medicine to nutraceuticals, we know the technology, the companies and the people behind them. BiotechEast operates the Taiwan-focused English-language web portal.

fDi Intelligence is the largest FDI centre of excellence globally. Specialising in all areas relating to foreign direct investment and investment promotion, the full suite of services includes: location advertising to generate brand awareness; industry-leading intelligence tools to develop FDI strategies and identify potential investors; and tailored FDI events and investor roundtables to meet target companies and generate business leads. Products within the portfolio include fDi Markets, a database tracking crossborder greenfield investment on a real-time basis; fDi Benchmark, a database which benchmarks global locations on their attractiveness to foreign investors; and fDi Magazine.

FT Health
The essential briefing for decision makers in health

FT Health is a weekly guide to the news and analysis that matters for decision makers in government, healthcare, research, industry and policy-making around the world. Leading specialists curate the best articles from the FT and across the web and make the links between the big issues. FT Health signposts important coverage on topics including infectious and non-communicable disease, public health, healthcare policy and practice, public health, research, development, drugs, vaccines and diagnostics. Straight to your inbox every Friday.’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.

Download our latest country report on 

Ireland Here

Greece Here

Switzerland Here

Pharma China ( is the most trusted English media and business intelligence service covering the Chinese pharmaceutical / biopharmaceutical industry and market. 

Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most multinational pharmaceutical companies, leading CROs, investment banks and consulting firms active in China as well as relevant industry associations and government agencies.

- Pharma China Journal Edition (monthly in PDF and Print)

- Pharma China Web Edition (continuously-updated news, in-depth commentaries and online databases) 

- China Pharmaceutical Guide (the most comprehensive and authoritative reference for China’s healthcare sector)

Pharma Focus Asia is a bi-annual magazine from Ochre Media Pvt. Ltd. Pharma Focus Asia covers important issues and trends shaping the future of the Pharma industry across Asia and rest of the world. It is the leading Pharma title in print as well as digital versions serving the information needs of key executives from the world’s leading pharmaceutical companies.

PharmaVOICE magazine, reaches more than 41,000 qualified subscribers and 100,000 users with its digital edition. PharmaVOICE is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE provides readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including Social Media, WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts.

Exclusive PR Partner (1)

About Spurwing Communications

Spurwing Communications prides itself on being a leading public and investor relations agency dedicated solely to working with healthcare sector clients.  We provide strategic counsel to corporations, Boards, senior decision makers and executives on critical communications programmes and challenges. From our Asia regional office in Singapore, Spurwing’s senior team provides cross-border comprehensive financial and corporate communications advice to some of the world’s most prominent and innovative healthcare corporations around-the-clock.

Contact us

Speaking Opportunities
Bina Jang
Senior Content Editor
Delegate Booking And Registration Enquiries
Pamela Lam
Conference Executive
Sponsorship Opportunities
Joe Hames
Commercial Manager, Global Industries
Media Partner And Press Enquiries
Vian Fu
Marketing and Campaign Executive

Last Year Event

Details of the FT Asia Healthcare & Life Sciences Summit 2016 can be found here.